Abstract
To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS Vaccines / administration & dosage
-
AIDS Vaccines / adverse effects
-
AIDS Vaccines / immunology*
-
Adult
-
Female
-
HIV Antibodies / blood
-
HIV Infections / blood
-
HIV Infections / immunology*
-
HIV-1 / immunology*
-
Headache / chemically induced
-
Humans
-
Immunization Schedule
-
Immunization*
-
Injections, Intramuscular
-
Male
-
Recombinant Proteins / immunology
-
env Gene Products, Human Immunodeficiency Virus / biosynthesis
-
env Gene Products, Human Immunodeficiency Virus / immunology*
Substances
-
AIDS Vaccines
-
HIV Antibodies
-
Recombinant Proteins
-
env Gene Products, Human Immunodeficiency Virus
-
gp140 envelope protein, Human immunodeficiency virus 1